Alkermes plc. Selling, General and Administrative Expense
Alkermes plc. (ALKS) reported Selling, General and Administrative Expense of $217.63 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-28.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-07-28
- Alkermes plc. selling, general and administrative expense for the quarter ending 2026-06-30 was $217.63M, a 27.38% increase year-over-year.
- Alkermes plc. selling, general and administrative expense for the quarter ending 2026-03-31 was $264.59M, a 54.10% increase year-over-year.
- Alkermes plc. selling, general and administrative expense for the quarter ending 2025-12-31 was $187.20M, a 27.35% increase year-over-year.
- Alkermes plc. selling, general and administrative expense for the quarter ending 2025-09-30 was $171.77M, a 14.22% increase year-over-year.
- Alkermes plc. selling, general and administrative expense for fiscal 2025 was $701.52M, a 8.72% increase from fiscal 2024.
- Alkermes plc. selling, general and administrative expense for fiscal 2024 was $645.24M, a 6.45% decline from fiscal 2023.
- Alkermes plc. selling, general and administrative expense for fiscal 2023 was $689.75M, a 16.76% increase from fiscal 2022.
- Alkermes plc. selling, general and administrative expense for fiscal 2022 was $590.75M, a 7.49% increase from fiscal 2021.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 3 month as first filed | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 6 month as first filed | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 9 month as first filed | Selling, General and Administrative Expense 12 month | Selling, General and Administrative Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $217.63M 10-Q · filed 2026-07-28 | $482.22M 10-Q · filed 2026-07-28 | $669.41M derived: sum of 3 quarters · filed 2026-07-28 | $841.19M derived: sum of 4 quarters · filed 2026-07-28 | ||||
| 2026-03-31 | $264.59M 10-Q · filed 2026-05-05 | $451.79M derived: sum of 2 quarters · filed 2026-05-05 | $623.56M derived: sum of 3 quarters · filed 2026-05-05 | $794.41M derived: sum of 4 quarters · filed 2026-07-28 | ||||
| 2025-12-31 | $187.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $358.97M derived: sum of 2 quarters · filed 2026-02-25 | $529.82M derived: sum of 3 quarters · filed 2026-07-28 | $701.52M 10-K · filed 2026-02-25 | ||||
| 2025-09-30 | $171.77M 10-Q · filed 2025-10-28 | $342.62M derived: sum of 2 quarters · filed 2026-07-28 | $514.33M 10-Q · filed 2025-10-28 | $661.32M derived: sum of 4 quarters · filed 2026-07-28 | ||||
| 2025-06-30 | $170.85M 10-Q · filed 2026-07-28 | $342.55M 10-Q · filed 2026-07-28 | $489.55M derived: sum of 3 quarters · filed 2026-07-28 | $639.93M derived: sum of 4 quarters · filed 2026-07-28 | ||||
| 2025-03-31 | $171.70M 10-Q · filed 2026-05-05 | $318.70M derived: sum of 2 quarters · filed 2026-05-05 | $469.08M derived: sum of 3 quarters · filed 2026-05-05 | $637.19M derived: sum of 4 quarters · filed 2026-05-05 | ||||
| 2024-12-31 | $146.99M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $297.38M derived: sum of 2 quarters · filed 2026-02-25 | $465.49M derived: sum of 3 quarters · filed 2026-02-25 | $645.24M 10-K · filed 2026-02-25 | ||||
| 2024-09-30 | $150.38M 10-Q · filed 2025-10-28 | $318.50M derived: sum of 2 quarters · filed 2025-10-28 | $498.24M 10-Q · filed 2025-10-28 | $668.03M derived: sum of 4 quarters · filed 2026-02-25 | ||||
| 2024-06-30 | $168.11M 10-Q · filed 2025-07-29 | $347.86M 10-Q · filed 2025-07-29 | $517.65M derived: sum of 3 quarters · filed 2026-02-25 | $674.02M derived: sum of 4 quarters · filed 2026-02-25 | ||||
| 2024-03-31 | $179.75M 10-Q · filed 2025-05-01 | $349.54M derived: sum of 2 quarters · filed 2026-02-25 | $505.91M derived: sum of 3 quarters · filed 2026-02-25 | $701.67M derived: sum of 4 quarters · filed 2026-02-25 | ||||
| 2023-12-31 | $169.79M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $326.16M derived: sum of 2 quarters · filed 2026-02-25 | $521.92M derived: sum of 3 quarters · filed 2026-02-25 | $689.75M 10-K · filed 2026-02-25 | ||||
| 2023-09-30 | $156.37M 10-Q · filed 2024-10-24 | $169.45M 10-Q · filed 2023-10-25 | $352.13M derived: sum of 2 quarters · filed 2024-10-24 | $519.96M 10-Q · filed 2024-10-24 | $549.18M 10-Q · filed 2023-10-25 | $662.51M derived: sum of 4 quarters · filed 2025-02-12 | ||
| 2023-06-30 | $195.76M 10-Q · filed 2024-07-24 | $205.26M 10-Q · filed 2023-07-26 | $363.59M 10-Q · filed 2024-07-24 | $379.74M 10-Q · filed 2023-07-26 | $506.13M derived: sum of 3 quarters · filed 2025-02-12 | $658.91M derived: sum of 4 quarters · filed 2025-02-12 | ||
| 2023-03-31 | $167.83M 10-Q · filed 2024-05-01 | $174.48M 10-Q · filed 2023-04-26 | $310.38M derived: sum of 2 quarters · filed 2025-02-12 | $463.15M derived: sum of 3 quarters · filed 2025-02-12 | $613.53M derived: sum of 4 quarters · filed 2025-02-12 | |||
| 2022-12-31 | $142.54M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | $295.32M derived: sum of 2 quarters · filed 2025-02-12 | $445.70M derived: sum of 3 quarters · filed 2025-02-12 | $590.75M 10-K · filed 2025-02-12 | $605.75M 10-K · filed 2023-02-16 | |||
| 2022-09-30 | $152.78M 10-Q · filed 2023-10-25 | $303.15M derived: sum of 2 quarters · filed 2023-10-25 | $448.21M 10-Q · filed 2023-10-25 | $597.25M derived: sum of 4 quarters · filed 2024-02-21 | ||||
| 2022-06-30 | $150.38M 10-Q · filed 2023-07-26 | $295.43M 10-Q · filed 2023-07-26 | $444.47M derived: sum of 3 quarters · filed 2024-02-21 | $580.68M derived: sum of 4 quarters · filed 2024-02-21 | ||||
| 2022-03-31 | $145.05M 10-Q · filed 2023-04-26 | $294.09M derived: sum of 2 quarters · filed 2024-02-21 | $430.31M derived: sum of 3 quarters · filed 2024-02-21 | $569.49M derived: sum of 4 quarters · filed 2024-02-21 | ||||
| 2021-12-31 | $149.04M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-21 | $285.25M derived: sum of 2 quarters · filed 2024-02-21 | $424.44M derived: sum of 3 quarters · filed 2024-02-21 | $549.61M 10-K · filed 2024-02-21 | $560.98M 10-K · filed 2022-02-16 | |||
| 2021-09-30 | $136.21M 10-Q · filed 2022-11-02 | $275.40M derived: sum of 2 quarters · filed 2022-11-02 | $400.57M 10-Q · filed 2022-11-02 | $546.35M derived: sum of 4 quarters · filed 2023-02-16 | ||||
| 2021-06-30 | $139.19M 10-Q · filed 2022-07-27 | $264.36M 10-Q · filed 2022-07-27 | $410.13M derived: sum of 3 quarters · filed 2023-02-16 | $537.79M derived: sum of 4 quarters · filed 2023-02-16 | ||||
| 2021-03-31 | $125.17M 10-Q · filed 2022-04-27 | $270.95M derived: sum of 2 quarters · filed 2023-02-16 | $398.60M derived: sum of 3 quarters · filed 2023-02-16 | $530.62M derived: sum of 4 quarters · filed 2023-02-16 | ||||
| 2020-12-31 | $145.78M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-16 | $273.43M derived: sum of 2 quarters · filed 2023-02-16 | $405.46M derived: sum of 3 quarters · filed 2023-02-16 | $538.83M 10-K · filed 2023-02-16 | ||||
| 2020-09-30 | $127.65M 10-Q · filed 2021-10-27 | $259.68M derived: sum of 2 quarters · filed 2021-10-27 | $393.05M 10-Q · filed 2021-10-27 | $547.50M derived: sum of 4 quarters · filed 2022-02-16 | ||||
| 2020-06-30 | $132.03M 10-Q · filed 2021-07-28 | $265.40M 10-Q · filed 2021-07-28 | $419.85M derived: sum of 3 quarters · filed 2022-02-16 | $568.55M derived: sum of 4 quarters · filed 2022-02-16 | ||||
| 2020-03-31 | $133.37M 10-Q · filed 2021-04-28 | $287.82M derived: sum of 2 quarters · filed 2022-02-16 | $436.53M derived: sum of 3 quarters · filed 2022-02-16 | $591.60M derived: sum of 4 quarters · filed 2022-02-16 | ||||
| 2019-12-31 | $154.45M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-16 | $303.15M derived: sum of 2 quarters · filed 2022-02-16 | $458.23M derived: sum of 3 quarters · filed 2022-02-16 | $599.45M 10-K · filed 2022-02-16 | ||||
| 2019-09-30 | $148.70M 10-Q · filed 2020-10-29 | $303.78M derived: sum of 2 quarters · filed 2020-10-29 | $445.00M 10-Q · filed 2020-10-29 | $586.22M derived: sum of 4 quarters · filed 2021-02-11 | ||||
| 2019-06-30 | $155.07M 10-Q · filed 2020-07-29 | $296.30M 10-Q · filed 2020-07-29 | $437.52M derived: sum of 3 quarters · filed 2021-02-11 | $566.30M derived: sum of 4 quarters · filed 2021-02-11 | ||||
| 2019-03-31 | $141.22M 10-Q · filed 2020-04-29 | $282.45M derived: sum of 2 quarters · filed 2021-02-11 | $411.22M derived: sum of 3 quarters · filed 2021-02-11 | $549.48M derived: sum of 4 quarters · filed 2021-02-11 | ||||
| 2018-12-31 | $141.23M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-11 | $270.00M derived: sum of 2 quarters · filed 2021-02-11 | $408.26M derived: sum of 3 quarters · filed 2021-02-11 | $526.41M 10-K · filed 2021-02-11 | ||||
| 2018-09-30 | $128.78M 10-Q · filed 2019-10-23 | $267.03M derived: sum of 2 quarters · filed 2019-10-23 | $385.18M 10-Q · filed 2019-10-23 | $496.08M derived: sum of 4 quarters · filed 2020-02-13 | ||||
| 2018-06-30 | $138.26M 10-Q · filed 2019-07-25 | $256.40M 10-Q · filed 2019-07-25 | $367.30M derived: sum of 3 quarters · filed 2020-02-13 | $466.93M derived: sum of 4 quarters · filed 2020-02-13 | ||||
| 2018-03-31 | $118.15M 10-Q · filed 2019-04-25 | $229.04M derived: sum of 2 quarters · filed 2020-02-13 | $328.68M derived: sum of 3 quarters · filed 2020-02-13 | $437.63M derived: sum of 4 quarters · filed 2020-02-13 | ||||
| 2017-12-31 | $110.90M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-13 | $210.53M derived: sum of 2 quarters · filed 2020-02-13 | $319.48M derived: sum of 3 quarters · filed 2020-02-13 | $421.58M 10-K · filed 2020-02-13 | ||||
| 2017-09-30 | $99.63M 10-Q · filed 2018-10-23 | $208.58M derived: sum of 2 quarters · filed 2018-10-23 | $310.68M 10-Q · filed 2018-10-23 | $407.83M derived: sum of 4 quarters · filed 2019-02-15 | ||||
| 2017-06-30 | $108.95M 10-Q · filed 2018-07-26 | $211.05M 10-Q · filed 2018-07-26 | $308.19M derived: sum of 3 quarters · filed 2019-02-15 | $399.34M derived: sum of 4 quarters · filed 2019-02-15 | ||||
| 2017-03-31 | $102.10M 10-Q · filed 2018-04-26 | $199.24M derived: sum of 2 quarters · filed 2019-02-15 | $290.39M derived: sum of 3 quarters · filed 2019-02-15 | $386.51M derived: sum of 4 quarters · filed 2019-02-15 | ||||
| 2016-12-31 | $97.14M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-15 | $188.29M derived: sum of 2 quarters · filed 2019-02-15 | $284.41M derived: sum of 3 quarters · filed 2019-02-15 | $374.13M 10-K · filed 2019-02-15 | ||||
| 2016-09-30 | $91.14M 10-Q · filed 2017-10-26 | $187.27M derived: sum of 2 quarters · filed 2017-10-26 | $276.99M 10-Q · filed 2017-10-26 | $364.46M derived: sum of 4 quarters · filed 2018-02-16 | ||||
| 2016-06-30 | $96.12M 10-Q · filed 2017-07-27 | $185.84M 10-Q · filed 2017-07-27 | $273.31M derived: sum of 3 quarters · filed 2018-02-16 | $362.81M derived: sum of 4 quarters · filed 2018-02-16 | ||||
| 2016-03-31 | $89.72M 10-Q · filed 2017-04-27 | $177.19M derived: sum of 2 quarters · filed 2018-02-16 | $266.69M derived: sum of 3 quarters · filed 2018-02-16 | $338.23M derived: sum of 4 quarters · filed 2018-02-16 | ||||
| 2015-12-31 | $87.47M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-16 | $176.97M derived: sum of 2 quarters · filed 2018-02-16 | $248.51M derived: sum of 3 quarters · filed 2018-02-16 | $311.56M 10-K · filed 2018-02-16 | ||||
| 2015-09-30 | $89.50M 10-Q · filed 2016-11-02 | $161.04M derived: sum of 2 quarters · filed 2016-11-02 | $224.09M 10-Q · filed 2016-11-02 | $278.89M derived: sum of 4 quarters · filed 2017-02-17 | ||||
| 2015-06-30 | $71.54M 10-Q · filed 2016-07-28 | $134.59M 10-Q · filed 2016-07-28 | $189.39M derived: sum of 3 quarters · filed 2017-02-17 | $241.28M derived: sum of 4 quarters · filed 2017-02-17 | ||||
| 2015-03-31 | $63.05M 10-Q · filed 2016-04-28 | $117.85M derived: sum of 2 quarters · filed 2017-02-17 | $169.74M derived: sum of 3 quarters · filed 2017-02-17 | $220.41M derived: sum of 4 quarters · filed 2017-02-17 | ||||
| 2014-12-31 | $54.80M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-17 | $106.69M derived: sum of 2 quarters · filed 2017-02-17 | $157.35M derived: sum of 3 quarters · filed 2017-02-17 | $199.91M 10-K · filed 2017-02-17 | ||||
| 2014-09-30 | $51.89M 10-Q · filed 2015-10-29 | $102.55M derived: sum of 2 quarters · filed 2015-10-29 | $145.10M 10-Q · filed 2015-10-29 | $189.27M derived: sum of 4 quarters · filed 2016-02-25 | ||||
| 2014-06-30 | $50.66M 10-Q · filed 2015-07-30 | $93.21M 10-Q · filed 2015-07-30 | $137.38M derived: sum of 3 quarters · filed 2016-02-25 | $176.84M derived: sum of 4 quarters · filed 2016-02-25 | ||||
| 2014-03-31 | $42.55M 10-Q · filed 2015-04-30 | $86.72M derived: sum of 2 quarters · filed 2016-02-25 | $126.17M derived: sum of 3 quarters · filed 2016-02-25 | $159.11M derived: sum of 4 quarters · filed 2016-02-25 | ||||
| 2013-12-31 | $44.17M derived: 10-K 9 month − 10-Q 6 month · filed 2016-02-25 | $83.63M derived: sum of 2 quarters · filed 2016-02-25 | $116.56M 10-K · filed 2016-02-25 | $151.24M derived: sum of 4 quarters · filed 2016-02-25 | ||||
| 2013-09-30 | $39.45M 10-Q · filed 2014-10-29 | $72.39M 10-Q · filed 2013-10-31 | $107.07M 10-Q · filed 2014-10-29 | $136.93M derived: sum of 4 quarters · filed 2014-10-29 | ||||
| 2013-06-30 | $32.93M 10-Q · filed 2014-07-31 | $67.61M 10-Q · filed 2014-07-31 | $97.48M derived: sum of 3 quarters · filed 2014-07-31 | $128.91M derived: sum of 4 quarters · filed 2014-07-31 | ||||
| 2013-03-31 | $34.68M 10-Q · filed 2014-04-30 | $64.55M derived: sum of 2 quarters · filed 2014-04-30 | $95.97M derived: sum of 3 quarters · filed 2014-04-30 | $125.76M 10-K · filed 2015-02-24 | ||||
| 2012-12-31 | $29.87M 10-Q · filed 2013-01-31 | $61.30M derived: sum of 2 quarters · filed 2013-10-31 | $91.08M 10-Q · filed 2013-01-31 | $125.51M derived: sum of 4 quarters · filed 2014-02-27 | ||||
| 2012-09-30 | $31.43M 10-Q · filed 2013-10-31 | $61.21M 10-Q · filed 2013-10-31 | $95.64M derived: sum of 3 quarters · filed 2014-02-27 | $131.11M derived: sum of 4 quarters · filed 2014-02-27 | ||||
| 2012-06-30 | $29.78M 10-Q · filed 2013-07-25 | $64.22M derived: sum of 2 quarters · filed 2014-02-27 | $99.69M derived: sum of 3 quarters · filed 2014-02-27 | $135.92M derived: sum of 4 quarters · filed 2014-02-27 | ||||
| 2012-03-31 | $34.43M derived: 10-KT 12 month − 10-Q 9 month · filed 2014-02-27 | $69.90M derived: sum of 2 quarters · filed 2014-02-27 | $106.14M derived: sum of 3 quarters · filed 2014-02-27 | $137.63M 10-KT · filed 2014-02-27 | ||||
| 2011-12-31 | $35.47M 10-Q · filed 2013-01-31 | $71.70M derived: sum of 2 quarters · filed 2013-01-31 | $103.20M 10-Q · filed 2013-01-31 | $127.36M derived: sum of 4 quarters · filed 2013-05-23 | ||||
| 2011-09-30 | $36.23M 10-Q · filed 2012-11-01 | $67.73M 10-Q · filed 2012-11-01 | $91.89M derived: sum of 3 quarters · filed 2013-05-23 | $112.42M derived: sum of 4 quarters · filed 2013-05-23 | ||||
| 2011-06-30 | $31.50M 10-Q · filed 2012-07-26 | $55.66M derived: sum of 2 quarters · filed 2013-05-23 | $76.18M derived: sum of 3 quarters · filed 2013-05-23 | $94.62M derived: sum of 4 quarters · filed 2013-05-23 | ||||
| 2011-03-31 | $24.16M derived: 10-K 12 month − 10-Q 9 month · filed 2013-05-23 | $44.69M derived: sum of 2 quarters · filed 2013-05-23 | $63.12M derived: sum of 3 quarters · filed 2013-05-23 | $82.85M 10-K · filed 2013-05-23 | ||||
| 2010-12-31 | $20.52M 10-Q · filed 2012-02-02 | $38.96M derived: sum of 2 quarters · filed 2012-02-02 | $58.68M 10-Q · filed 2012-02-02 | |||||
| 2010-09-30 | $18.44M 10-Q · filed 2011-11-03 | $38.16M 10-Q · filed 2011-11-03 | ||||||
| 2010-03-31 | $76.51M 10-K · filed 2012-05-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |